{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Bermekimab",
  "nciThesaurus": {
    "casRegistry": "1401965-15-8",
    "chebiId": "",
    "chemicalFormula": "",
    "definition": "A \"true human\" (cloned from human B lymphocytes) monoclonal antibody directed against interleukin-1 alpha (IL1a) with potential antineoplastic activity. Bermekimab binds to IL1a and may block the activity of IL1a. IL1a, an inflammatory mediator, plays a key role in interleukin-mediated tumor cell activity such as angiogenesis, tissue matrix remodeling, metastasis and tumor cell invasion.",
    "fdaUniiCode": "N6SVN735GY",
    "identifier": "C95708",
    "preferredName": "Bermekimab",
    "semanticType": "Immunologic Factor",
    "subclassOf": [
      "C129822",
      "C20401"
    ],
    "synonyms": [
      "BERMEKIMAB",
      "Bermekimab",
      "CA-18C3",
      "CV 18C3",
      "CV-18C3",
      "MABp1",
      "RA 18C3",
      "RA-18C3"
    ]
  }
}